Long-acting reversible contraception
Long acting reversible contraception: the effective and appropriate use of long-acting reversible contraception
| Guidance type: Clinical guideline |
| Date issued: October 2005 |
| Expected review date: October 2009 |
| Reference: CG30 |
SummaryThe NICE clinical guideline on long-acting reversible contraception (LARC) offers the best-practice advice for all women of reproductive age who may wish to regulate their fertility by using LARC methods. It covers specific issues for the use of these methods during the menarche and before the menopause, and by particular groups, including women who have HIV, learning disabilities or physical disabilities, or are younger than 16 years. June 2006: The recommendation on treating irregular bleeding after insertion of a contraceptive implant has been changed (this is recommendation 1.5.4.2 in the NICE guideline). Although the evidence does show that mifepristone is effective at controlling irregular bleeding associated with implants, it is not licensed for this indication. The revised recommendation reads: 'Irregular bleeding associated with implant use can be treated with mefenamic acid or ethinylestradiol.' |
| Top |
DocumentsFor healthcare professionals
For patients, carers and the publicBackground information |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below:
|
| Top |
